Importance of Myocardial Perfusion Positron Emission Tomography Recognized in New Joint Position Statement by the American Society of Nuclear Cardiology and the Society of Nuclear Medicine and Molecular Imaging

CardioGen-82 (Rubidium Rb 82 Generator) is the only U.S. FDA-approved generator-based PET perfusion agent for the evaluation of patients with suspected or existing coronary artery disease.

Partner News | Published: Wednesday, August 31, 2016 9:00 am

by PR Newswire


MONROE TOWNSHIP, N.J., Aug. 29, 2016 /PRNewswire/ -- Bracco Diagnostics Inc. (BDI), the U.S. subsidiary of Bracco Imaging S.p.A., a global leading company in the diagnostic imaging business, announced today that the American Society for Nuclear Cardiology (ASNC) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have e-published a Position Statement to explain why myocardial perfusion positron emission tomography (PET) is most useful in the diagnosis and management of coronary artery disease (CAD), and to provide guidance as to when it should be considered for optimal patient care.i

The Position Paper states that, in view of its high diagnostic accuracy, strong prognostic power, low radiation dose, and consistent high-quality images, myocardial perfusion PET should be considered the preferred, first-line test for all patients who meet the appropriate criteria for a stress imaging test, are unable to complete a diagnostic-level of exercise, and require pharmacologic stress. Myocardial perfusion PET is also the recommended test when previous stress imaging is equivocal, of poor quality or inconclusive, in high-risk patients in whom diagnostic errors carry even greater clinical implications, in patients with certain body characteristics that commonly affect image quality, and in younger patients to minimize accumulated life-time radiation exposure.

Read the full news story here.

This site uses cookies to improve your experience.

By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.